跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 11 天前精选AI 评分21

TriSalus Life Sciences 提交第三季度业绩公告的 8-K 文件

TriSalus Life Sciences, Inc. (0001826667) (Filer)

AI 导读

TriSalus Life Sciences 于 11 月 10 日提交 8-K,称已发布截至 9 月 30 日的第三季度财务业绩公告。公告作为附件 99.1 纳入文件;该 8-K 正文未列出具体业绩数据。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2026

TRISALUS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39813

85-3009869

(State or other jurisdiction of

incorporation or organization)

(Commission
File Number)

(I.R.S. Employer

Identification No.)

6272 W 91st Ave, Westminster, Colorado

80031
(Address of principal executive office)(Zip Code)

(888) 321-5212

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.0001 par valueTLSI

Nasdaq Global Market

Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per shareTLSIW

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02Results of Operations and Financial Conditions.

On November 10, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and it will not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

Item 9.01Financial Statements and Exhibits.
(d) Exhibits:
Exhibit NumberDescription

99.1

Press Release dated November 10, 2026

104Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 10, 2026

TriSalus Life Sciences, Inc.
By:/s/ David Patience
Name:David Patience
Title:Chief Financial Officer

来源:SEC EDGAR · 本站存档